Phase I data show early efficacy in the majority of patients and a very favourable safety profile HASSELT, Belgium and CHEPSTOW, Wales, April 16, 2018 -- (Healthcare Sales & Marketing Network) -- Apitope, a clinical stage biotech company developing pot... Biopharmaceuticals Apitope, Graves' Disease, Multiple Sclerosis, autoimmune disease (Source: HSMN NewsFeed)

Read full article on